Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M

Celldex Therapeutics, Inc.

Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.
Net proceeds expected ~$376.2M after underwriting discounts and expenses.
Underwriters granted 30-day option to purchase up to an additional 1,278,000 shares.
Proceeds to fund clinical/preclinical development of barzolvolimab, bispecific antibody platform, and pipeline.
Offering expected to close on or about March 5, 2024, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC valued at approximately $376.2 million (effective 2024-02-29).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC and Cowen and Company, LLC
Value: approximately $376.2 million
Effective: 2024-02-29

Exact text from the filing

On February 29, 2024, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 8,520,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $47.00 per share (the “Offering”). The net proceeds to the Company from the Offering are expected to be approximately $376.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-029969

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.